Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine

Cancer Letters

Volumn 250, Issue 2, 2007, Pages 311-322

  Nair, Sandhya K ^a   Verma, Arti ^a   Thomas, T J ^a   Chou, T C ^c   Gallo, Michael A ^a,b   Shirahata, Akira ^d   Thomas, Thresia ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d JOSAI UNIVERSITY   (Japan)

Author keywords

2 Methoxyestradiol; Apoptosis; Breast cancer cells; Polyamine analogue

Indexed keywords

2 METHOXYESTRADIOL; BROXURIDINE; CYCLIN D1; NORSPERMINE; PROTEIN KINASE B; PUTRESCINE; SPERMIDINE; SPERMINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MICROTUBULE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN D1; DRUG SYNERGISM; ESTRADIOL; HUMANS; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SPERMINE;

EID: 34047240000     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.10.027     Document Type: Article

References (56)

1. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr. Opin. Oncol. 15 (2003) 425-430
2. Gokmen-Polar Y., Escuin D., Walls C.D., Soule S.E., Wang Y., Sanders K.L., Lavallee T.M., Wang M., Guenther B.D., Giannakakou P., and Sledge Jr. G.W. β-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 65 (2005) 9406-9414
3. Han G.Z., Liu Z.J., Shimoi K., and Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res. 65 (2005) 387-393
4. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., and Van Waes C. 2-Methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin. Cancer Res. 10 (2004) 8665-8673
5. Fowke J.H., Qi D., Bradlow H.L., Shu X.O., Gao Y.T., Cheng J.R., Jin F., and Zheng W. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids 68 (2003) 65-72
6. Zhu B.T., and Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis?. Cancer Res. 58 (1998) 2269-2277
7. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q., Shu X.O., and Gao Y.T. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 147-150
8. Liehr J.G., Ricci M.J., Jefcoate C.R., Hannigan E.V., Hokanson J.A., and Zhu B.T. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. USA 92 (1995) 9220-9224
9. Russo J., Hasan L.M., Balogh G., Guo S., and Russo I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem Mol. Biol. 87 (2003) 1-25
10. 125I-labelled ligand. Acta Endocrinol. (Copenh) 103 (1983) 282-288
11. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 11 (2005) 6625-6633
12. Lakhani N.J., Sarkar M.A., Venitz J., and Figg W.D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23 (2003) 165-712
13. D'Amato R.J., Lin C.M., Flynn E., Folkman J., and Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA 91 (1994) 3964-3968
14. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesanno R., Nawroth P.P., and Schwelgerer L. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368 (1994) 237-239
15. Golebiewska J., Rozwadowski P., Spodnik J.H., Knap N., Wakabayashi T., and Wozniak M. Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. Acta Biochim. Pol. 49 (2002) 59-65
16. Vijayanathan V., Venkiteswaran S., Nair S.K., Verma A., Thomas T.J., Zhu B.T., and Thomas T. Physiological levels of 2-methoxyestradiol interfere with nongenomic signaling of 17β-Estradiol in human breast cancer cells. Clinical Cancer Res. 12 (2006) 2038-2048
17. Huang P., Feng L., Oldham E.A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
18. Liu Z.J., and Zhu B.T. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J. Steroid Biochem. Mol. Biol. 88 (2004) 265-275
19. Thomas T., Balabhadrapathruni S., Gallo M.A., and Thomas T.J. Development of polyamine analogs as cancer therapeutic agents. Oncol. Res. 13 (2002) 123-135
20. Gerner E.W., and Meyskens Jr. F.L. Polyamines and cancer: old molecules, new understanding. Nat. Rev. Cancer 4 (2004) 781-792
21. Huang Y., Pledgie A., Casero Jr. R.A., and Davidson N.E. Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 16 (2005) 229-241
22. Dolan M.E., Fleig M.J., Feuerstein B.G., Basu H.S., Luk G.D., Casero Jr. R.A., and J Marton L. Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. Cancer Res. 54 (1994) 4698-4702
23. Canizares F., Salinas J., de las Heras M., Diaz J., Tovar I., Martinez P., and Penafiel R. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin. Cancer Res. 5 (1999) 2035-2041
24. Thomas T., and Thomas T.J. Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res. Treat. 29 (1994) 101-189
25. 11-diethylnorspermine administered by multiple injection or continuous infusion. Clin. Cancer Res. 1 (1995) 847-857
26. 11-diethylnorspermine in patients with non-small cell lung cancer. Clin. Cancer Res. 8 (2002) 684-690
27. 11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 9 (2003) 5922-5928
28. Kumar R., and Hung M.C. Signaling intricacies take center stage in cancer cells. Cancer Res. 65 (2005) 2511-2515
29. Thompson J.E., and Thompson C.B. Putting the rap on Akt. J. Clin. Oncol. 22 (2004) 4217-4226
30. Tokunaga E., Kimura Y., Oki E., Ueda N., Futatsugi M., Mashino K., et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int. J. Cancer 118 (2005) 284-289
31. Stal O., Perez-Tenorio G., Akerberg L., Olsson B., Nordenskjold, Skoog L., and Rutqvist L.E. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 5 (2003) R37-R44
32. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 1 (2002) 707-717
33. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D.S., and Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem. 276 (2001) 9817-9824
34. Ariazi E.A., Ariazi J.L., Cordera F., and Jordan V.C. Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6 (2006) 181-202
35. Thomas T., Gallo M.A., and Thomas T.J. Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases. Curr. Cancer Drug Targets 4 (2004) 483-499
36. Lee A.J., Kosh J.W., Conney A.H., and Zhu B.T. Characterization of the NADPH-dependent metabolism of 17β-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J. Pharmacol. Exp. Ther. 298 (2001) 420-432
37. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006) 621-681
38. Chou T.C., and Talalay P. Quantitiative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Ad. Enzyme Regul. 22 (1984) 27-55
39. T.C. Chou, N. Martin, CompuSyn for Drug Combinations: PC Software and User's Guide. A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. ComboSyn, Paramus, NJ, 2005.
40. Chou T.C., Motzer R.J., Tong Y., and Bosl G.J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl Cancer Inst. 86 (1994) 1517-1524
41. Lewis J.S., Thomas T.J., Pestell R.G., Albanese C., Gallo M.A., and Thomas T. Differential effects of 16α-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J. Mol. Endocrinol. 34 (2005) 91-105
42. Ray G., Dhar G., Van Veldhuizen P.J., Banerjee S., Saxena N.K., Sengupta K., and Banerjee S.K. Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 45 (2006) 3703-3713
43. Chen B., Pan H., Zhu L., Deng Y., and Pollard J.W. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase- > AKT- > GSK-3β- > cyclin D1- > pRB pathway to block uterine epithelial cell proliferation. Mol. Endocrinol. 19 (2005) 1978-1990
44. Fernando R.I., and Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol. Biol. Cell 15 (2004) 3266-3284
45. Radu A., Neubauer V., Akagi T., Hanafusa H., and Georgescu M.M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell Biol. 23 (2003) 6139-6149
46. Wolff J. Promotion of microtubule assembly by oligocations: cooperativity between charged groups. Biochemistry 37 (1998) 10722-10729
47. Nogales E. Structural insight into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 30 (2001) 397-420
48. Flusberg D.A., Numaguchi Y., and Ingber D.E. Cooperative control of Akt phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal microfilaments and microtubules in capillary endothelial cells. Mol. Biol. Cell 12 (2001) 3087-3094
49. Mollinedo F., and Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8 (2003) 413-450
50. Blajeski A.L., Phan V.A., Kottke T.J., and Kaufmann S.H. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J. Clin. Invest. 110 (2002) 91-99
51. Kramer D.L., Vujcic S., Diegelman P., Alderfer J., Miller J.T., Black J.D., Bergeron R.J., and Porter C.W. Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. Cancer Res. 59 (1999) 1278-1286
52. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V., and Cheng J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 61 (2001) 5985-5991
53. Chauhan D., Li G., Auclair D., Hideshima T., Richardson P., Podar K.N., et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 101 (2003) 3606-3614
54. 2 in polyamine analogue-treated human breast cancer cell lines. J. Biol. Chem. 280 (2005) 39843-39851
55. Gao N., Rahmani M., Dent P., and Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 24 (2005) 3797-3809
56. Urata Y., Ihara Y., Murata H., Goto S., Koji T., Yodoi J., Inoue S., and Kondo T. 17 Beta-estradiol protects against oxidative stress-induced cell death through the glutathione/glutaredoxin-dependent redox regulation of Akt in myocardiac H9c2 cells. J. Biol. Chem. 281 (2006) 13092-13102